▍March 25, 2026 · Guangzhou
On March 25, 2026, Professor Xu Guibin, Director of the Department of Urology and doctoral supervisor at the Fifth Affiliated Hospital of Guangzhou Medical University, successfully completed the first clinical implantation in China of the MimoPath™ metal‑covered ureteral coated stent (referred to as the Mimo™ stent). As the first detachable, coated metal ureteral stent featuring a controlled tear‑line structure, its application in complex ureteral stricture cases fills a long‑standing clinical gap and represents a significant technological advancement.
▍Core Technologies
Developed entirely in‑house by Surgsci Medical Ltd. (Surgsci)—from materials and processes to proprietary equipment—the Mimo™ stent is the world’s first metal‑covered ureteral stent integrating multiple advanced technologies. Its key technical advantages include:
miCot™ Coating Technology Provides excellent adhesion and hydrophobicity, reducing biofilm attachment and enhancing safety during long‑term use.
unLoad™ Detachment Technology Features controllable and adjustable detachment force, ensuring reliable stent removal with a precise balance between tensile strength and ease of tearing.
Extended Size Range Offers a comprehensive range of specifications, with an effective length exceeding 200 mm, enabling coverage of long strictures or diseased segments to better accommodate complex anatomical needs.
Low‑Friction Surface Treatment Ensures smoother insertion and reduces deposition on the stent surface, extending its effective indwelling duration.
Segment‑Specific Reinforcement Design Provides targeted reinforcement at the stricture site while maintaining a large drainage lumen, delivering precise segmental support and better conformity to complex urinary tract anatomy.
▍Clinical Significance
The significance of this first clinical implantation extends far beyond the completion of a single procedure.
Complex ureteral strictures have long posed challenges due to long lesion segments, complicated anatomy, limited indwelling duration of traditional stents, insufficient drainage efficiency, and surface deposition that compromises outcomes. Clinicians urgently need a ureteral stent that can remain in place long‑term, be removed safely and controllably, allow smooth insertion, and provide precise support at the stricture site.
For many years, China has lacked competitive domestic solutions in the field of covered ureteral stents, leaving clinicians with limited choices.
The successful implantation of the Mimo™ stent marks a major breakthrough in the treatment of complex ureteral strictures using domestically developed covered stents. It provides urologists with an innovative and clinically practical new option and represents an important milestone in advancing high‑performance ureteral endoluminal devices.
▍About Surgsci
As the full‑stack developer of the MimoPath™ stent, Surgsci Medical Ltd. continues to advance innovation in minimally invasive urological devices. This clinical application further demonstrates Surgsci’s engineering capabilities and its commitment to delivering meaningful solutions for clinical practice.
